Priorities & Actions
Parkinson's Plan 2006
Parkinson's Matrix
Research Agenda

Research Resources

Animal Models

Antibody Resources
Clinical Research
Gene Therapy
Genetic Resources
Brain Banks Across the
   United States

Funding Research
Funding Announcements
Clinical Trials
Related Literature

Research Centers
NIH Intramural Research
Udall Centers of
   Excellence

Patient/Caregiver Information
Parkinson's Disease
PD Clinical Trials

Contact Us
My Privacy

NINDS is part of the
National Institutes of
Health

Download Adobe Reader

  Print-friendly version

   Email this page

Join our electronic mailing list

Mouse

Chemical Lesion Models

Chemical	Administration	Phenotype	Reference
MPTP**	Systemic
MPTP + maneb	Systemic	Exacerbation of MPTP phenotype on locomotion and catalepsy.	Takahashi, et al. Res Commun Chem Pathol Pharmacol 1989; 66(1):167-70.
MPTP + Probenicid	Systemic	Chronic loss of dopamine, gradual loss of nigral neurons. Motor decline as assessed by rotorod.	Petroske, et al. Neuroscience 2001;106(3):589-601.
6-OHDA***	Stereotactic injection	Acute nigrostriatal denervation. Dose-dependent amphetamine and apomorphine-induced circling.	Przedborski, et al. Neuroscience 1995; 67(3):631-47.
Paraquat	Systemic	Loss of nigrostriatal neurons and terminals. Reduced ambulatory activity.	Brooks, et al. Brain Res 1999; 823(1-2):1-10
Paraquat + maneb	Systemic	Cell loss in substantia nigra, reduced TH and dopamine.	Thiruchelvam, et al. J Neurosci 2000; 20(24):9207-14.
3 nitrotyrosine	Intrastriatal injection	Acute striatal degeneration, TH loss, ipsilateral turning behavior with amphetamine.	Mihm, et al. J Neurosci 2001; 21(11):RC149.

*note: combined use of pesticides or toxins tends to give enhanced phenotype.
**note: MPTP toxicity varies with different mouse strains. For review of 7 strains, see: Hamre, et al. Brain Res 1999; 828:91-103.
***note: rats more commonly used with 6-OHDA due to well-established stereotactic technique and lower costs.

Last updated June 01, 2007